SCHEMBL3021020

SCHEMBL3021020

Cc1ccc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4c(C(C)C)cc(C(C)C)cc4C(C)C)CC3)n2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.34
OGA O60502 2/20 0.33
ALDH1A1 P00352 2/20 0.33
DNM1L O00429 10/20 0.33
HRH3 Q9Y5N1 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
FABP4 P15090 2/20 0.32
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
CYP2C9 P11712 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
FABP3 P05413 1/20 0.31
FABP5 Q01469 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018020 0.90 ALDH1A1 (0.35) OGAALDH1A1DNM1LHRH3SMN1; SMN2
SCHEMBL3016738 0.89 SMN1; SMN2 (0.36) OGAALDH1A1DNM1LHRH3SMN1; SMN2
SCHEMBL3007229 0.88 ALDH1A1 (0.34) OGAALDH1A1DNM1LHRH3FABP4
SCHEMBL3002541 0.87 OGA (0.33) OGAALDH1A1DNM1LHRH3SMN1; SMN2
SCHEMBL3019284 0.87 DNM1L (0.35) ALDH1A1DNM1LHRH3MAPT
SCHEMBL3005123 0.87 ALDH1A1 (0.34) OGAALDH1A1DNM1LHRH3FABP4
SCHEMBL3004088 0.87 ALDH1A1 (0.35) OGAALDH1A1DNM1LHRH3FABP4
SCHEMBL3014904 0.86 AR (0.38) ARALDH1A1DNM1LSMN1; SMN2NPC1
SCHEMBL3019563 0.86 ALDH1A1 (0.38) AROGAALDH1A1SMN1; SMN2RAB9A
SCHEMBL3011506 0.86 ALDH1A1 (0.34) OGAALDH1A1DNM1LHRH3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885OGA 2888/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.